$TYRA

Tyra Biosciences, Inc.

Tyra Biosciences is a clinical-stage biotechnology company headquartered in Carlsbad, California. It develops precision medicines for patients with cancer and genetically defined conditions, focusing on Fibroblast Growth Factor Receptor biology. Its in-house SNÅP platform uses protein crystallography, cell-based assays and animal models to design oral small molecule drug candidates. Tyra retains full development and commercialization rights to its pipeline. Tyra’s lead candidate, oral dabogratinib, is in Phase 2 trials for urothelial cancers and achondroplasia in children. Its other clinical programs include TYRA-430, being evaluated in a Phase 1 trial focused on hepatocellular carcinoma, and TYRA-200, being evaluated in a Phase 1 trial focused on intrahepatic cholangiocarcinoma resistant to previous FGFR inhibitors.

1
0
1

No SEC Form 4 filings for $TYRA in the last 30 days.

See all $TYRA insider activity →

Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences (TYRA) reported Q3 2026 results, highlighting initial Phase 2 data for dabogratinib in IR NMIBC, showing 79% ORR and 64% CR. The company raised $400M, extending its cash runway to 2030. It plans Phase 3 trials for dabogratinib in 2027. R&D and G&A expenses increased, with a net loss of $51.1M for the quarter.

TYRA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning TYRA (Tyra Biosciences, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.

Recent TYRA coverage spans financial news, technology and earnings.

What's driving TYRA

AlphAI scores every news story that mentions TYRA with an AI model for sentiment and relevance, and aggregates insider trades from Tyra Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TYRA

Score
$TYRAHighAI 8/10

Raymond James reiterates Strong Buy on Tyra Biosciences stock

Raymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.

Related tickers